PharmaBlock Sciences Nanjing Inc
SZSE:300725
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CN |
|
PharmaBlock Sciences Nanjing Inc
SZSE:300725
|
8.6B CNY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
932.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
271B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
236.2B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.8B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
287.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
153.8B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121B USD |
Loading...
|
Market Distribution
| Min | -2 148% |
| 30th Percentile | 14.3% |
| Median | 23% |
| 70th Percentile | 34.6% |
| Max | 775.2% |
Other Profitability Ratios
PharmaBlock Sciences Nanjing Inc
Glance View
PharmaBlock Sciences (Nanjing), Inc. engages in the innovation of chemistry products and services throughout the pharmaceutical research and development process. The company is headquartered in Nanjing, Jiangsu and currently employs 1,735 full-time employees. The company went IPO on 2017-11-10. The firm's primary products include aromatic heterocyclic drug molecular building blocks, common saturated alicyclic drug molecular building blocks, four-membered ring drug molecular building blocks and special saturated ring drug molecular building blocks. The firm is also involved in development, production and sales of pharmaceutical intermediates, and provides technical services related to the development and process production of pharmaceutical molecular building blocks.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for PharmaBlock Sciences Nanjing Inc is 30.9%, which is below its 3-year median of 38.2%.
Over the last 3 years, PharmaBlock Sciences Nanjing Inc’s Gross Margin has decreased from 46.2% to 30.9%. During this period, it reached a low of 30.9% on Sep 30, 2025 and a high of 46.2% on Sep 30, 2022.
